omacetaxine for CML
Selected indexed studies
- Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. (Am J Hematol, 2024) [PMID:39093014]
- Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. (Am J Hematol, 2022) [PMID:35751859]
- Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate). (Neoplasma, 2016) [PMID:27268912]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Omacetaxine mepesuccinate in chronic myeloid leukemia. (2014) pubmed
- Homoharringtonine and omacetaxine for myeloid hematological malignancies. (2014) pubmed
- Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia. (2014) pubmed
- Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. (2024) pubmed
- Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. (2022) pubmed
- Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate). (2016) pubmed
- Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. (2020) pubmed
- Omacetaxine (Synribo) for CML. (2015) pubmed
- A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia. (2016) pubmed
- Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine? (2014) pubmed